Medicare beneficiaries taking a statin in 2026 are almost always prescribed one of two generics: atorvastatin (brand name Lipitor) or rosuvastatin (brand name Crestor). Both molecules lost patent protection years ago, atorvastatin in November 2011 and rosuvastatin in 2016, and both are now manufactured by more than a dozen FDA-approved generic makers. Because of that competition, every Medicare Part D standalone prescription drug plan (PDP) and every Medicare Advantage prescription drug plan (MAPD) places generic atorvastatin and generic rosuvastatin on its lowest formulary tiers, Tier 1 (preferred generic) or Tier 2 (generic), for 2026.
Tier placement translates directly into copay amounts. A Tier 1 preferred generic copay on most 2026 Part D plans runs $0 to $5 for a 30-day supply, and a Tier 2 generic copay runs $5 to $10. Brand-name Lipitor and Crestor, when a plan still carries them at all, usually sit on Tier 3 (preferred brand) or higher, with copays or coinsurance far above the generic rate. Patients who fill a brand-name statin without checking their plan's tier first are frequently the ones who end up disputing an unexpectedly high pharmacy bill. Reviewing your plan's 2026 formulary through the Medicare Plan Finder at medicare.gov before your annual enrollment period ends is the single most effective way to confirm which tier your statin sits on.
Neither atorvastatin nor rosuvastatin appears on the list of drugs selected for Medicare price negotiation under the Inflation Reduction Act of 2022, and neither has a negotiated Maximum Fair Price for 2026. CMS selects negotiation candidates from single-source brand-name drugs with the highest total Medicare Part D spending and no generic competition. Because atorvastatin and rosuvastatin already have robust generic markets driving prices down to $3 to $18 a month, they do not meet the negotiation criteria and do not need to. All statin spending, whether generic or brand, still counts toward the 2026 Medicare Part D annual out-of-pocket cap of $2,100 set by the same law. For readers comparing this page against the broader class overview, see the statins cost comparison page and the standalone atorvastatin cost breakdown.
What Statins on Medicare Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same statins on medicare can cost many times more at a hospital than at your local pharmacy:
2026 Statins on Medicare Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Medicare Part D / Medicare Advantage, Tier 1 generic (2026) | $0 - $5/month copay | Generic atorvastatin and rosuvastatin are Tier 1 preferred generics on nearly every 2026 formulary. No prior authorization for standard cardiovascular doses. |
| Medicare Extra Help / Low-Income Subsidy (2026) | $0 - $4.90/prescription | Dual-eligible and full-subsidy beneficiaries pay the statutory Extra Help generic copay, capped at $4.90 for generics in 2026. Apply through the Social Security Administration. |
| Cash pharmacy price, generic (no insurance) | $3 - $18/month | Costco, Walmart, Kroger, CVS, and Walgreens all sell generic atorvastatin and rosuvastatin under $20 a month with a free coupon. Often cheaper than a commercial copay. |
| Brand-name Lipitor or Crestor without insurance | $300 - $700/month | Brand-name statins retail far above the generic price. Ask your pharmacist for the FDA-approved bioequivalent generic before paying cash for the brand. |
| Medicaid | $1 - $4/prescription | All 50 states cover generic statins as preferred drugs. Copay varies by state; some states charge $0 for preferred generics. |
| Inpatient hospital charge | $50 - $300/tablet | Facility-rate markup applies even to a $3-a-month generic when dispensed during an inpatient stay. Medicare Part A pays the facility, not the drug's retail rate. |
Statins are oral Part D drugs with no Medicare Part B ASP rate and no HCPCS J-code. Copay ranges reflect 2026 CMS Part D benefit design and formulary survey data. Cash prices reflect 2026 GoodRx pricing verified September 2026.
Source: CMS Medicare Part D 2026 benefit parameters, Medicare Extra Help program rules, GoodRx 2026 pricing
Why Hospitals Charge So Much
Hospital pharmacies bill oral medications, including statins, at facility rates that bundle drug acquisition cost with nursing administration, pharmacy dispensing, storage, and overhead. A generic atorvastatin tablet that a hospital pharmacy acquires for under $0.50 can appear on an itemized inpatient bill at $50 to $300 per dose. A Medicare beneficiary admitted for a cardiac procedure who continues a daily statin during a 4-day stay can see $200 to $1,200 in statin charges on the itemized bill, for a medication that costs $3 to $18 a month at any retail pharmacy.
Medicare Part A covers the inpatient stay and its drugs under the hospital's diagnosis-related group (DRG) payment, so the statin's inflated line-item charge does not usually generate a separate patient bill for Medicare beneficiaries without a Part A deductible or coinsurance liability tied to the stay itself. The itemized statin charge still matters for patients disputing a facility's total billed charges, for beneficiaries with a Medicare Advantage plan applying per-day copays, and for anyone reviewing a hospital bill for accuracy. Requesting the itemized bill and the National Drug Code (NDC) for each statin line is the fastest way to verify the charge against the drug's known retail price.
Patient Assistance Programs
Pfizer (maker of brand Lipitor) and AstraZeneca (maker of brand Crestor) both run manufacturer patient assistance programs available to Medicare beneficiaries who cannot afford the brand-name product and have a documented clinical reason they cannot switch to the generic. Most Medicare beneficiaries never need a PAP for a statin because generic atorvastatin and rosuvastatin already carry a $0 to $10 Part D copay or a $3 to $18 cash price.
Patient assistance programs for Statins on Medicare| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Pfizer RxPathways Patient Assistance Program (Lipitor) | Free brand-name Lipitor for Medicare Part D/Medicare Advantage patients with household income at or below 300% FPL who cannot afford the copay | pfizerrxpathways.com |
| AstraZeneca AZ&Me Prescription Savings Program (Crestor) | Free brand-name Crestor for Medicare beneficiaries and uninsured patients at or below 300% FPL for primary care products | azandme.com |
| Medicare Extra Help (Low-Income Subsidy) | Reduces generic statin copay to $0 - $4.90/prescription for qualifying low-income Medicare beneficiaries in 2026 | ssa.gov/extrahelp |
| GoodRx Free Coupon | Reduces generic statin cash prices to $3 to $18 a month at most major chains; no application or income documentation required | goodrx.com |
Manufacturer savings cards and coupons are blocked by federal anti-kickback statute (42 U.S.C. Section 1320a-7b) for anyone enrolled in Medicare, Medicaid, TRICARE, or VA benefits. Medicare beneficiaries cannot use a Lipitor or Crestor manufacturer coupon at the pharmacy counter. Use the income-based Pfizer RxPathways or AZ&Me patient assistance program instead, or ask your Part D plan to apply the Extra Help low-income subsidy if you qualify.
Source: Pfizer RxPathways (pfizerrxpathways.com), AstraZeneca AZ&Me (azandme.com), Social Security Administration Extra Help program
Medicare Part D
Medicare Part D and Medicare Advantage prescription drug plans place generic atorvastatin and generic rosuvastatin on Tier 1 (preferred generic) or Tier 2 (generic) on virtually every 2026 formulary, with copays of $0 to $10 for a 30-day supply. There is no statin-specific monthly cap under the Inflation Reduction Act, unlike the $35 insulin cap. Instead, statin costs count toward the general 2026 Medicare Part D annual out-of-pocket cap of $2,100, after which a beneficiary pays $0 for all covered drugs for the rest of the calendar year. Because generic statins are so inexpensive, reaching the $2,100 cap from statin spending alone is essentially impossible.
CMS did not select atorvastatin or rosuvastatin for Inflation Reduction Act Medicare price negotiation, and neither drug has a Maximum Fair Price for 2026. The negotiation program targets single-source brand drugs with high total Medicare spending and no generic competition, such as Eliquis and Jardiance. Statins already have robust generic competition driving cash prices to $3 to $18 a month, so a negotiated price would add no additional savings. Brand-name Lipitor and Crestor remain on some formularies as Tier 3 or Tier 4 drugs at far higher cost, but no Medicare beneficiary needs to pay that price when the bioequivalent generic is available at a fraction of the cost.
Dual-eligible Medicare beneficiaries, meaning those who also qualify for Medicaid, and beneficiaries approved for the Extra Help (Low-Income Subsidy) program typically pay $0 to $4.90 for a generic statin fill in 2026. Extra Help applications go through the Social Security Administration at ssa.gov/extrahelp or a local Social Security office, and most applicants who qualify for full Extra Help pay nothing at all for a generic statin for the rest of the plan year. Beneficiaries choosing between a standalone Part D plan and a Medicare Advantage plan during the October 15 to December 7 open enrollment window should compare each plan's specific statin tier placement using the Medicare Plan Finder before enrolling, since tier placement can shift year to year.
Common Statins on Medicare Billing Errors
If your Part D plan charges more than $10 for a generic statin, or your hospital bill shows $50 or more per statin tablet, check for these common billing errors before paying:
- Brand-name Lipitor or Crestor billed to Part D when the pharmacy actually dispensed the generic: this can inflate your copay to the Tier 3 brand rate instead of the Tier 1 generic rate. Confirm the NDC on your receipt matches the generic manufacturer.
- Wrong formulary tier applied at the pharmacy: if your explanation of benefits shows a Tier 3 copay for a drug that should be Tier 1, ask the pharmacist to reprocess the claim with the correct National Drug Code.
- Extra Help subsidy not applied even though you are approved: dual-eligible and full-subsidy beneficiaries should never pay more than $4.90 for a generic statin in 2026. If your receipt shows a higher amount, ask the pharmacy to verify your Low-Income Subsidy status with the plan.
- Inpatient charge for a dose that was clinically held: statins are sometimes held before a procedure or during a restricted diet order. A held dose still appearing as a billed charge is a standard dispute item.
- Prior authorization denial not appealed on a Medicare Advantage plan: generic statin denials are rare, but if one occurs, request a written coverage determination and ask your prescriber to file a redetermination request within 60 days.
Frequently Asked Questions
How much does a statin cost on Medicare in 2026?
Generic atorvastatin (Lipitor) and generic rosuvastatin (Crestor) sit on Tier 1 or Tier 2 of nearly every 2026 Medicare Part D and Medicare Advantage formulary, with copays running $0 to $10 for a 30-day supply. Dual-eligible beneficiaries on Extra Help pay $0 to $4.90. Brand-name Lipitor or Crestor, if your plan still covers them, sit on a higher tier with a copay well above the generic rate. All statin costs count toward the 2026 Part D annual out-of-pocket cap of $2,100.
Is there a generic for Lipitor and Crestor?
Yes. Generic atorvastatin (Lipitor) has been available since November 2011, and generic rosuvastatin (Crestor) has been available since 2016. More than a dozen FDA-approved manufacturers produce each generic as of 2026. There are no biosimilars for either drug because statins are small-molecule synthetic drugs, not biologics. Medicare Part D places both generics on its lowest formulary tiers, making the brand-name version unnecessary for most beneficiaries.
How do I apply for the patient assistance program for brand-name Lipitor or Crestor?
For Lipitor, apply through Pfizer RxPathways at pfizerrxpathways.com or call 1-844-989-PATH (7284). For Crestor, apply through AstraZeneca's AZ&Me program at azandme.com or call 1-800-292-6363. Both accept Medicare Part D and Medicare Advantage enrollees with household income at or below 300 percent of the federal poverty level. Processing takes 7 to 14 business days. Most Medicare patients can skip the PAP entirely by switching to the $0 to $10 generic copay instead.
Can I use a Lipitor or Crestor manufacturer coupon with Medicare?
No. Federal anti-kickback statute (42 U.S.C. Section 1320a-7b) bars manufacturer copay coupons from being used by anyone enrolled in Medicare, Medicaid, TRICARE, or VA benefits. Manufacturer coupons for brand Lipitor and Crestor are restricted to commercially insured patients only. If you are on Medicare and need help affording a statin, apply for Medicare Extra Help through the Social Security Administration or use the income-based Pfizer RxPathways or AZ&Me patient assistance program.
Does the IRA negotiated Medicare price apply to statins?
No. Neither atorvastatin nor rosuvastatin was selected for Inflation Reduction Act Medicare price negotiation, and neither has a Maximum Fair Price for 2026. CMS selects negotiation candidates from brand-name drugs with high Medicare spending and no generic competition, such as Eliquis and Jardiance. Statins already have generic competition holding prices to $3 to $18 a month, so no negotiation was necessary. All Part D drug spending, statins included, still falls under the general 2026 annual out-of-pocket cap of $2,100.
What does a statin cost without insurance at the pharmacy counter?
Generic atorvastatin costs $3 to $9 a month at Costco and Walmart without insurance, and $10 to $25 at CVS or Walgreens with a free coupon. Generic rosuvastatin runs $9 to $18 a month at most major chains with a coupon. Brand-name Lipitor and Crestor retail for $300 to $700 a month without insurance. Anyone paying more than $25 a month for a generic statin should show the pharmacist a free GoodRx coupon before paying cash.
What if my Medicare plan denies coverage for my statin?
Generic statin denials on Medicare are rare because nearly every Part D and Medicare Advantage plan covers at least two statins on Tier 1. If denied, request a written coverage determination, then ask your prescriber to file a formulary exception or prior authorization documenting clinical necessity. If still denied, file a Level 1 redetermination within 60 days, then escalate to an Independent Review Entity. Switching to the covered generic provides immediate access while an appeal is pending.
Do I qualify for the Pfizer RxPathways or AZ&Me patient assistance program?
To qualify in 2026, your household income must be at or below 300 percent of the federal poverty level: $47,880 for one person, $99,000 for a family of four. You also need a valid brand-name prescription, Medicare Part D or Medicare Advantage enrollment (or no insurance), and a documented reason the generic is not appropriate. Commercially insured patients are not eligible for either program. Most Medicare beneficiaries qualify for a $0 to $10 generic copay instead and never need to apply.
